ArriVent BioPharma Reports Second Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: Aug 11, 2025
NEWTOWN SQUARE, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the second quarter ended June 30, 2025, and highlighted recent Company progress.
Read more at globenewswire.com
